Spots Global Cancer Trial Database for A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
Official Title: A Phase 1b Study of INCMGA00012 (PD-1 Inhibitor), INCB001158 (Arginase Inhibitor), and the Combination in Japanese Participants With Advanced Solid Tumors
Study ID: NCT03910530
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability and the pharmacokinetics (PK) of INCMGA00012 (PD-1 Inhibitor), INCB001158 (Arginase Inhibitor), and the combination in Japanese participants with advanced solid tumor malignancies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center Hospital, Chuo Ku, , Japan
National Cancer Center Hospital East, Kashiwa, , Japan
Contact Details
Name: Eiji Ueda, MD, PhD, MBA
Affiliation: Incyte Biosciences Japan GK
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
